Deltec Asset Management LLC Sells 3,000 Shares of Illumina, Inc. (NASDAQ:ILMN)

Deltec Asset Management LLC lowered its stake in shares of Illumina, Inc. (NASDAQ:ILMN) by 40.0% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 4,500 shares of the life sciences company’s stock after selling 3,000 shares during the quarter. Deltec Asset Management LLC’s holdings in Illumina were worth $601,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Zacks Investment Management bought a new stake in shares of Illumina in the 3rd quarter worth $2,924,000. Freemont Management S.A. purchased a new position in Illumina during the third quarter worth about $1,565,000. Assenagon Asset Management S.A. grew its position in Illumina by 5.8% in the 4th quarter. Assenagon Asset Management S.A. now owns 42,748 shares of the life sciences company’s stock worth $5,712,000 after purchasing an additional 2,338 shares in the last quarter. CCLA Investment Management increased its stake in Illumina by 20.5% in the 4th quarter. CCLA Investment Management now owns 535,050 shares of the life sciences company’s stock valued at $71,493,000 after buying an additional 91,122 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. lifted its position in shares of Illumina by 65.5% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 32,806 shares of the life sciences company’s stock worth $4,278,000 after buying an additional 12,986 shares in the last quarter. 89.42% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on ILMN. Stephens upped their target price on Illumina from $170.00 to $184.00 and gave the company an “overweight” rating in a report on Tuesday, November 12th. Piper Sandler decreased their target price on Illumina from $195.00 to $185.00 and set an “overweight” rating for the company in a research report on Monday, November 11th. UBS Group boosted their price target on shares of Illumina from $133.00 to $145.00 and gave the stock a “neutral” rating in a report on Tuesday, November 5th. Barclays decreased their price objective on shares of Illumina from $145.00 to $130.00 and set an “equal weight” rating for the company in a report on Monday. Finally, Morgan Stanley dropped their target price on shares of Illumina from $156.00 to $150.00 and set an “equal weight” rating on the stock in a research note on Monday, January 13th. Eight analysts have rated the stock with a hold rating, eleven have assigned a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, Illumina has a consensus rating of “Moderate Buy” and an average price target of $164.84.

Illumina Trading Down 5.3 %

Shares of ILMN opened at $124.20 on Wednesday. Illumina, Inc. has a twelve month low of $100.08 and a twelve month high of $156.66. The stock has a market cap of $19.70 billion, a PE ratio of -12.47 and a beta of 1.10. The company has a quick ratio of 1.85, a current ratio of 2.43 and a debt-to-equity ratio of 0.94. The business’s 50-day moving average price is $138.19 and its 200-day moving average price is $135.50.

Illumina (NASDAQ:ILMN) last posted its earnings results on Monday, November 4th. The life sciences company reported $1.14 earnings per share for the quarter, topping analysts’ consensus estimates of $0.88 by $0.26. Illumina had a negative net margin of 36.10% and a positive return on equity of 7.29%. The business had revenue of $1.08 billion for the quarter, compared to analyst estimates of $1.08 billion. During the same quarter in the prior year, the firm posted $0.33 EPS. Illumina’s revenue was down 3.5% on a year-over-year basis. On average, equities analysts forecast that Illumina, Inc. will post 4.13 EPS for the current fiscal year.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.